Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
12:15pm, Wednesday, 22'nd Apr 2026
Moderna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines.
Moderna starts late-stage trial of bird flu vaccine in US, UK
07:13pm, Tuesday, 21'st Apr 2026
Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the U.S. and the UK, marking the first time a pandemic bird flu vaccine made with mRNA technolog
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
07:01pm, Tuesday, 21'st Apr 2026
Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April 2
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
10:00am, Tuesday, 21'st Apr 2026
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on it
Moderna wins EU approval for combined flu, COVID shot for older adults
09:59am, Tuesday, 21'st Apr 2026
Moderna said on Tuesday the European Commission had granted marketing authorization for a combination vaccine for the prevention of influenza and COVID-19 in adults 50
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized product mCOMBRIAX will be made available in the European Union, sub
Moderna to Present at Upcoming Conferences in May 2026
07:00am, Tuesday, 21'st Apr 2026
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: BofA Securities 2026 Healthcare Confer
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TP
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
06:50pm, Wednesday, 15'th Apr 2026
Moderna (MRNA) closed the most recent trading day at $54.26, moving +2.69% from the previous trading session.
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
07:00am, Wednesday, 15'th Apr 2026
CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its
Stock Market Today (LIVE): PPI Beats Fear, But Oil Risks Loom; Novo's OpenAI Deal Lifts Shares
09:33am, Tuesday, 14'th Apr 2026
Top insights from the latest market news from Tuesday, April 14, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors
06:50pm, Thursday, 09'th Apr 2026
In the latest trading session, Moderna (MRNA) closed at $51.3, marking a -1.54% move from the previous day.
Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy?
07:10am, Thursday, 09'th Apr 2026
In an uncertain market, investors have rushed to get in on these players seen as “safer” investments. They operate in the areas of healthcare and retail, selling treatments and products that are e
Bank of America flags international opportunities as key growth driver for Moderna
01:01pm, Wednesday, 08'th Apr 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results, according to analysts at Bank of America. T
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 08'th Apr 2026
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
